Literature DB >> 6585178

Induction of hemoglobin synthesis in human leukemic K 562 cells by adriamycin.

P Jeannesson, L Ginot, M Manfait, J C Jardillier.   

Abstract

The antitumor compound adriamycin was found to induce differentiation-associated properties in human erythroleukemia K 562 cells. Studies on the relationship between drug concentration and the appearance of hemoglobin demonstrated that the more the rate of cell division was reduced during the 4 days of exposure, the higher was the accumulation of hemoglobin per cell. Considering the variation in the intracellular protein content during the response, it appears that adriamycin (40 nM) stimulated the synthesis of both hemoglobin and non-hemoglobin proteins while hemin, a well-known erythroid inducer, specifically increased hemoglobin synthesis. In addition, the lack of cell growth was associated with a recruitment of benzidine-positive cells. In contrast to hemin, adriamycin did not modify the electrophoretic pattern found in untreated cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6585178

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Role of protein kinase C in adriamycin-induced erythroid differentiation of K562 cells.

Authors:  R Hoffman; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Comparative effects of fagaronine, adriamycin and aclacinomycin on K562 cell sensitivity to natural-killer-mediated lysis. Lack of agreement between alteration of transferrin receptor and CD15 antigen expressions and induction of resistance to natural killer.

Authors:  H Benoist; L Comoe; P Joly; Y Carpentier; A Desplaces; J Dufer
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.